@article{ATM31812,
author = {Daniele Focosi and Marco Tuccori and Fabrizio Maggi},
title = {Checkpoint inhibitors and progressive multifocal leukoencephalopathy: friends of foes?},
journal = {Annals of Translational Medicine},
volume = {7},
number = {Suppl 8},
year = {2019},
keywords = {},
abstract = {Progressive multifocal leukoencephalopathy (PML) has evolved in the last decade from a disorder of acquired immune deficiency syndrome (AIDS) patients into a rare but fatal complication of several life-saving therapeutics (ranging from rituximab in non-Hodgkin lymphomas to natalizumab in multiple sclerosis). PML is linked to opportunistic reactivation of the latent human JC polyomavirus (JCV), which leads to emergence of neurotropic strains causing brain demyelination.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/31812}
}